Benjamin Webster

Postgraduate Research Student
BSc (Hons) Chemistry

Academic and research departments

Department of Chemistry.

My publications


R. R Trinder, Tz Kokalova, D. J Parker, C Wheldon, B Phoenix, P Ivanov, B Russel, BENJAMIN LUKE WEBSTER, PATRICK HENRY REGAN, A Robinson, D Cullen, S Pells, R Allen, S Pirrie, A Turner, P Santa Rita (2020)Theragnostics - Alternative production of terbium isotopes at the University of Birmingham using an MC40 cyclotron, In: Journal of Physics. Conference Series1643(1) IOP Publishing

In this work alternative methods for the production of terbium isotopes, and in particular 152Tb and 155Tb, have been investigated. These isotopes, which could be used for theragnostics, have been produced using an alpha and a proton beam incident on europium and gadolinium targets, respectively. The experimental results have been compared with the predicted cross-sections, calculated using TALYS and PACE4 code.

Ben Webster, Peter Ivanov, Ben Russell, Sean Collins, Thierry Stora, Joao Pedro Ramos, Ulli Köster, Andrew Paul Robinson, David Read (2019)Chemical Purification of Terbium-155 from Pseudo-Isobaric Impurities in a Mass Separated Source Produced at CERN, In: Scientific Reports9(1)10884 Nature Publishing Group

Four terbium radioisotopes (149, 152, 155, 161Tb) constitute a potential theranostic quartet for cancer treatment but require any derived radiopharmaceutical to be essentially free of impurities. Terbium-155 prepared by proton irradiation and on-line mass separation at the CERN-ISOLDE and CERN-MEDICIS facilities contains radioactive 139Ce16O and also zinc or gold, depending on the catcher foil used. A method using ion-exchange and extraction chromatography resins in two column separation steps has been developed to isolate 155Tb with a chemical yield of ≥95% and radionuclidic purity ≥99.9%. Conversion of terbium into a form suitable for chelation to targeting molecules in diagnostic nuclear medicine is presented. The resulting 155Tb preparations are suitable for the determination of absolute activity, SPECT phantom imaging studies and pre-clinical trials.